Viscom SE (FRA:V6C)
Germany · Delayed Price · Currency is EUR | Market Cap | 42.65M |
| Revenue (ttm) | 85.24M |
| Net Income (ttm) | -7.75M |
| Shares Out | n/a |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | 19.55 |
| Dividend | 0.05 (1.08%) |
| Ex-Dividend Date | May 30, 2024 |
| Volume | 2,000 |
| Average Volume | 1,640 |
| Open | 4.640 |
| Previous Close | 4.720 |
| Day's Range | 4.640 - 4.640 |
| 52-Week Range | 2.650 - 5.300 |
| Beta | n/a |
| RSI | 54.07 |
| Earnings Date | Aug 14, 2025 |
About Intra-Cellular Therapies
Viscom SE develops, manufactures, and sells inspection systems for industrial production applications in Europe, the Americas, and Asia. The company offers products for solder paste inspection, optical inspection, X-ray inspection, conformal coating inspection, battery inspection, and bond inspection, as well as software solutions. It also provides application support, trainings, maintenance, and reconstruction and modernization services. The company serves its products to various industries, such as automotive electronics, industrial and consu... [Read more]
Financial Performance
Financial StatementsNews
Viscom SE: Strong Q1 2025 Growth, Full-Year Forecast Confirmed
Viscom SE has kicked off 2025 with a promising start, showcasing notable growth and strategic foresight. With a 9.4% surge in orders and a significant turnaround in EBIT, the company is on a path to r...
EQS-News: Viscom SE reports positive business development in the first quarter of 2025; Executive Board confirms full-year forecast
EQS-News: Viscom SE / Key word(s): Quarter Results Viscom SE reports positive business development in the first quarter of 2025; Executive Board confirms full-year forecast 20.05.2025 / 08:00 CET/CEST...